Category: Wall Street Beat
Scorned Biolase ex-CEO Federico Pignatelli withdraws his lawsuit as the company urges shareholders to welcome new leadership and deny his bid for re-election to the board.
Former Biolase (NSDQ:BIOL) CEO Federico Pignatelli agreed this week to withdraw his lawsuit against the dental devices maker, but he's still pursuing his personal investigation into the company's recent conduct.
Lantheus Medical Imaging spikes plans for a $125 million initial public offering, citing 'poor market conditions.'
Lantheus Medical Imaging reportedly spiked an initial public offering it hoped would raise $125 million, citing "poor market conditions," Renaissance Capital reported.
Teleflex gets some Wall Street love after reporting double-digit revenue growth in Q2, beating analysts' expectations and raising its adjusted per-share earnings guidance for the rest of the year.
Wayne, Pa.-based Teleflex (NYSE:TFX) served up some good news today with strong numbers for its 2nd quarter and an increased outlook on the year.
The company posted an 11.4% increase in sales and an 11.3% increase in profits, with adjusted earnings coming in almost 19% higher year-over-year.
Here's a look at some of the top Wall Street stories for medical device companies this week: Smith & Nephew CEO reveals new 'no frills' strategy; Bard: We're on track for early 2015 Lutonix approval; Ocular Therapeutix prices IPO below range; Philips' healthcare business suffers in Q2; Intersect ENT prices IPO at low end of range
MRI diagnostics maker T2 Biosystems releases details on its initial public offering, hoping to raise as much as $78.2 million at $17 per share.
Massachusetts-based T2 Biosystems raised its hopes for its upcoming initial public offering, raising its maximum aggregate take to $78.2 million if shares sell at $17 apiece.
Edwards Lifesciences boosts its full-year guidance as sales surge in Q2, and the company pads its bottom line with a $750 million settlement from Medtronic.
Edwards Lifesciences (NYSE:EW) bumped its expectations for the year after posting a strong 2nd quarter with significant increases in its sales and profits.
Sluggish healthcare sales drag down Philips overall figures, but the company is eying a comeback for the 2nd half of the year.
Philips Healthcare (NYSE:PHG) had a tough 2nd quarter with a shutdown of a manufacturing facility in Cleveland taking some of the wind out of the sales for the entire company.